(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property **Organization** International Bureau





(43) International Publication Date 4 November 2004 (04.11.2004)

PCT

(10) International Publication Number WO 2004/094659 A1

(51) International Patent Classification7:

C12Q 1/68

(21) International Application Number:

PCT/EP2004/004178

(22) International Filing Date: 20 April 2004 (20.04.2004)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

60/464,372 60/526,689

21 April 2003 (21.04.2003) US 2 December 2003 (02.12.2003)

- (71) Applicant (for DE only): ROCHE DIAGNOSTICS GMBH [DE/DE]; Sandhofer Strasse 116, Mannheim (DE).
- (71) Applicant (for all designated States except DE): F. HOFF-MANN-LA ROCHE AG [CH/CH]; Grenzacherstrasse 124, CH-4070 Basel (CH).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): HIGUCHI, Russell, Gene [US/US]; 3258 Liberty Avenue, Alameda, CA 94501 (US). PELTZ, Gary, Allen [US/US]; 110 Danbury Lane, Redwood City, CA 94061 (US). FLJAL, Bonnie [US/US]; 59 Taurus Drive #3B, Hillsborough, NJ 08844 (US). RO, Sunhee, Kwon [KR/US]; 635 Greenwich Lane, Foster City, CA 94404 (US). LI, Jia [US/US]; 32801 Regents Boulevard, Union City, CA 94587 (US).
- (74) Common Representative: ROCHE DIAGNOSTICS GMBH; Patent Department, 68298 Mannheim (DE).
- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,

PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) for the following desig-
- of inventorship (Rule 4.17(iv)) for US only

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: ASSOCIATIONS OF POLYMORPHISMS IN THE FRZB GENE WITH OBESITY AND OSTEOPOROSIS

(57) Abstract: Methods and reagents for determining sequence variants present at the FRZB locus, which facilitate identifying individuals at risk for obesity and/or osteoporosis, are provided. In particular, methods for detecting an individual's risk for obesity and/or osteoporosis by detecting at least one polymorphism (e.g., at least one single nucleotide polymorphism) in the FRZB gene in a nucleic acid sample from the individual are provided. Related kits, arrays and systems are also described.